Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.

J Clin Endocrinol Metab · 2021 · PMC7823251 · PMID 33236115

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significanceP = .063so close (0.05 < p ≤ 0.1)

HOMA2-IR decreases with tirzepatide 15 mg compared with placebo and dulaglutide approached but did not reach statistical significance ( P = .063 and .067, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.